Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR-T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

Calcium intake appears to protect against colorectal cancer in individuals with certain gene variants, Vanderbilt researchers have discovered.

Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.

Nashville Predators goaltender Pekka Rinne, Predators executive leaders, executives from Tri Star Energy (Twice Daily) and team mascot Gnash recently presented the proceeds of the team’s 365 Pediatric Cancer Fund to Monroe Carell Jr. Children’s Hospital at Vanderbilt.

A compound identified at Vanderbilt represents a new lead for treating rare, aggressive childhood cancers called Ewing sarcomas.